Second-generation TKIs, dasatinib and nilotinib, retain binding in the presence of the majority of BCR-ABL1 kinase domain mutations because of improved topological fit to the enzyme 4, 5 and show promise in the treatment of patients with resistant disease. 6, 7 A 48-year-old male patient presented with fatigue and weight loss. Physical examination revealed splenomegaly of 7 cm. Initial laboratory evaluation revealed haemoglobin 10.6 g/100 ml, WBC 238 Â 10 9 /l and platelet count 445 Â 10 9 /l. Morphological analysis of the bone marrow revealed CML in chronic phase. Cytogenetic analysis showed 100% Philadelphia (Ph)-positive metaphases, FISH confirmed the p210 translocation and the presence of the BCR-ABL1 fusion gene was demonstrated using RQ-PCR; BCR-ABL1/ABL1 ratio was 56.9%, which was consistent with the diagnosis of CML.
Initially, the patient was treated with imatinib 400 mg daily, and 3 months following diagnosis he had a complete haematological response. However, a bone marrow aspirate 7 months following diagnosis indicated the persistence of 100% Ph-positive metaphases. Owing to an increase in the WBC count 3 months later, the dose of imatinib was increased to 600 mg, and a month later, it was further increased to 800 mg daily. There was no further haematological response, and metaphases remained 100% Ph positive. A year following diagnosis, the BCR-ABL1/ ABL1 ratio was 46.9% ( Figure 1 ).
In the absence of an HLA-compatible sibling, a search for an unrelated donor was initiated, and 18 months following diagnosis, a matched, unrelated donor peripheral blood SCT was performed using fludarabine, busulfan and antithymocyte globulin as the conditioning regimen. 8 Cyclosporin and methothrexate were administered as GVHD prophylaxis. Two months post-transplant, chimerism analysis indicated that the patient had a 96% donor profile, 9 and the BCR-ABL1/ABL1 ratio was 0.207%. 10 Three months later, chimerism analysis indicated that he had a 100% donor profile, and BCR-ABL1 transcripts were undetectable, indicating a complete molecular response.
A follow-up bone marrow 11 months post-transplant revealed no Ph-positive metaphases, but RQ-PCR analysis detected a 0.007% (positive) BCR-ABL1/ABL1 ratio, and this increased to 0.023% at 12 months. At 14 months posttransplant, the BCR-ABL1/ABL1 ratio increased to 0.495%, and this was accompanied by loss of the graft indicated by 86% donor chimera and the re-emergence of 8/20 Ph-positive metaphases.
In an attempt to reestablish the donor chimerism, the patient received three escalating doses of donor lymphocyte infusions (DLIs) at 19, 20 and 22 months post-transplant comprising 0.5, 1.0 and 3.6 CD3 Â 10 7 /kg, respectively. Donor chimerism continued to decrease to 15% and then to 1%. Concomitantly, the level of Ph-positive metaphases increased from 40% at 16 months to 74% at 20 months and 100% at 22 months, indicating the failure of DLI.
The patient's BCR-ABL1 kinase domain was examined for the presence of mutations by direct sequencing 2 years post-transplant on the basis of the failure of DLI to restore donor chimerism and rapidly increasing BCR-ABL1/ABL1 ratios.
1 Two BCR-ABL1 kinase domain mutations were identified by direct sequencing, each occurring at the V379 amino acid. The 'gta' codon normally coding for valine at this position mutated to both 'ata' coding for isoleucine and to 'cta' coding for leucine. The V379 residue lies adjacent to the BCR-ABL1 activation loop, 11 and mutation to isoleucine (V379I) or leucine (V379L) may inhibit binding of imatinib mesylate either directly by steric hindrance due to the bulkier residue or indirectly by increasing the entropy of ABL1, which is less favourable for inhibitor binding.
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Following identification of the V379I and V379L mutants, the patient was enrolled in a nilotinib clinical trial (CAMN107A2109) at a dose of 400 mg b.i.d. Nilotinib retains binding to the BCR-ABL1 kinase domain in V379I-mutated patients due to the incorporation of alternative binding groups to those in imatinib mesylate, 11 and this conformation may also be effective for the V379L mutation.
Three months after initiation of nilotinib, the patient had achieved a complete haematological response, and cytogenetic analysis did not reveal any Ph chromosome. Chimerism showed a 100% donor profile; however, the BCR-ABL1/ABL1 ratio was still weakly positive at 0.014%. Six months following commencement of nilotinib, the patient had a complete molecular response (Hb 14.1 g/ 100 ml, WBC 4.8 Â 10 9 /l, platelet count 142 Â 10 9 /l and BCR-ABL1 transcripts were undetectable) and remains in complete molecular remission 18 months following commencement of nilotinib.
Retrospective analysis by direct sequencing indicated that kinase domain mutations were undetectable at the time of presentation. However, 15 months following diagnosis the patient had developed a dominant Y253H mutation.
In summary, we describe a patient with Ph-positive CML who failed imatinib mesylate therapy with an acquired i.m. -resistant p-loop mutation (Y253H). He subsequently underwent an unrelated allogeneic SCT and became a donor chimera with no evidence of CML. Subsequent relapse associated with V379I/L mutations was unresponsive to DLI. Treatment with the second-generation tyrosine kinase inhibitor nilotinib resulted in complete molecular response and restoration of donor chimerism. These findings reflect a leukaemic stem cell, which over time gave rise to two clones mutated at different amino-acid residues. The Y253H clone was eradicated by the SCT and the V379L clone evolved post-transplant. This highlights the need for reassessment of the mechanism of resistance in patients who relapse post-transplant. 
